Ani Pharmaceuticals reported $50.93M in Gross Profit on Sales for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Aerie Pharmaceuticals AERI:US USD 29.2M 370K
Ani Pharmaceuticals ANIP:US USD 50.93M 12.37M
Aurora Cannabis Inc ACB:CN CAD -22824000 580K
Canopy Growth Corp WEED:CN CAD 3.82M 5.21M
Eli Lilly And LLY:US USD 5.36B 305M
Endo International Ordinary Shares ENDP:US USD 364.83M 28.49M
Hikma Pharmaceutical HIK:LN USD 623M 62M
Knight Therapeutics Inc GUD:CN CAD 30.4M 7.89M
Lannett LCI:US USD 12.6M 4.74M
Nektar Therapeutics NKTR:US USD 18.65M 2.18M
Novartis NVS:US USD 9.18B 151M
Perrigo Ordinary Shares PRGO:US USD 362.9M 9.2M
Sun Pharmaceuticals SUNP:IN INR 82.44B 3.83B
Teva Pharmaceutical TEVA:IT USD 1.71B 118M
Teva Pharmaceutical Industries TEVA:US USD 1.71B 118M